It does not seem easy for Dupixent, an atopic dermatitis treatment, to expand insurance benefits for children and adolescents. According to related industries, Standard of Sanofi-Aventis Korea's Dupixent 200mg was recently set. It is the first time in about a year since the application for expansion of benefits in March 2021. Dupixent's expansion of atopic dermatitis benefits for children and adolescents took seven months to start consulting experts last year. As it is an expensive new drug and it was not easy to register for the first time, it is judged that discussions on expansion are also difficult. Although detailed indications are different, there is a clear difference in speed compared to JAK inhibitors such as